** Swiss drugmaker Novartis NOVN.S is up around 2% to the top of Switzerland's blue-chip SMI index .SSMI after raising its 2026 core operating income guidance
** Vontobel says Q3 profitability "clearly" beat consensus despite weaker contributions from genericized products including Entresto, Promacta and Tasigna
** Shares up about 16% YTD as of previous close
($1 = 0.8273 Swiss francs)
Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk
